EP 0669982 A1 19950906 - MATERIALS COMPRISING AND METHODS OF PREPARATION AND USE FOR RIBOSOME-INACTIVATING PROTEINS.
Title (en)
MATERIALS COMPRISING AND METHODS OF PREPARATION AND USE FOR RIBOSOME-INACTIVATING PROTEINS.
Title (de)
RIBOSOMEN INAKTIVIERENDE PROTEINE ENTHALTENDE MATERIALIEN, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG.
Title (fr)
MATIERES COMPRENANT DES PROTEINES D'INACTIVATION DE RIBOSOMES, PROCEDES DE PREPARATION ET UTILISATION DE CES PROTEINES.
Publication
Application
Priority
- US 9209487 W 19921104
- US 78756791 A 19911104
- US 90170792 A 19920619
Abstract (en)
[origin: WO9309130A1] The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
IPC 1-7
IPC 8 full level
C12N 15/09 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61P 35/02 (2006.01); A61P 37/00 (2006.01); C07K 1/113 (2006.01); C07K 1/18 (2006.01); C07K 1/22 (2006.01); C07K 14/415 (2006.01); C07K 16/00 (2006.01); C07K 16/16 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 9/50 (2006.01); C12N 15/29 (2006.01); C12P 21/02 (2006.01); C12P 21/08 (2006.01); C12R 1/19 (2006.01); C12R 1/91 (2006.01)
CPC (source: EP US)
A61K 47/6825 (2017.08 - EP US); A61K 47/6849 (2017.08 - EP US); A61P 35/02 (2018.01 - EP); A61P 37/00 (2018.01 - EP); C07K 14/415 (2013.01 - EP US); C07K 16/16 (2013.01 - EP US); C07K 16/28 (2013.01 - EP US); C07K 16/2896 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); C07K 2317/24 (2013.01 - EP US); C07K 2317/54 (2013.01 - EP US); C07K 2317/55 (2013.01 - EP US); C07K 2317/622 (2013.01 - EP US); C07K 2319/00 (2013.01 - EP US); C07K 2319/034 (2013.01 - EP US); C07K 2319/33 (2013.01 - EP US); C07K 2319/55 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE
DOCDB simple family (publication)
WO 9309130 A1 19930513; AT E239792 T1 20030515; CA 2122714 A1 19930513; CA 2122714 C 20020806; DE 69233045 D1 20030612; DE 69233045 T2 20040212; EP 0669982 A1 19950906; EP 0669982 A4 19950102; EP 0669982 B1 20030507; EP 1344826 A1 20030917; JP 2004141153 A 20040520; JP 3759163 B2 20060322; JP H07504883 A 19950601; US 5376546 A 19941227; US 5416202 A 19950516
DOCDB simple family (application)
US 9209487 W 19921104; AT 92924279 T 19921104; CA 2122714 A 19921104; DE 69233045 T 19921104; EP 03002145 A 19921104; EP 92924279 A 19921104; JP 2003334432 A 20030925; JP 50870293 A 19921104; US 90170792 A 19920619; US 98843092 A 19921209